Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Navelbine Clear all
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 4:57 PM EDT
Recruiting Phase 2 Interventional

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559
View directory record Official record
Conditions
Breast Cancer, Metastatic
Interventions
Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
View directory record Official record
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

NCT00002813
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, vinorelbine tartrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Orange, California • Honolulu, Hawaii • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 25, 2026, 4:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

NCT02658084
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Vinorelbine, Trastuzumab Emtansine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 2 Interventional

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

NCT00003622
View directory record Official record
Conditions
Prostate Cancer
Interventions
paclitaxel, vinorelbine tartrate
Drug
Lead sponsor
James Ahlgren
Other
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

NCT00194727
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Vinorelbine, Capecitabine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 3 Interventional

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00017459
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, tirapazamine, vinorelbine tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
42
States / cities
Los Angeles, California • Oakland, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT04145349
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Vinorelbine in Treating Older Women With Stage IV Breast Cancer

NCT00022152
View directory record Official record
Conditions
Breast Cancer
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT00337194
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
monoclonal antibody SGN-30, placebo, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

NCT00153907
View directory record Official record
Conditions
Breast Cancer
Interventions
Navelbine, Capecitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00309998
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, vinorelbine tartrate
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 25, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 3 Interventional

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

NCT04943627
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cervical Cancer
Interventions
Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

NCT00002949
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions
paclitaxel, vinorelbine tartrate, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 25, 2026, 4:57 PM EDT
Terminated Phase 2Phase 3 Interventional

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

NCT02213744
View directory record Official record
Conditions
Breast Cancer, HER2 Positive Breast Cancer
Interventions
MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
70
States / cities
Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 2 Interventional

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

NCT00881387
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, gemcitabine hydrochloride, vinorelbine ditartrate
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

NCT00003584
View directory record Official record
Conditions
Kidney Cancer
Interventions
estramustine phosphate sodium, prednisone, vinorelbine tartrate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Up to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 25, 2026, 4:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

NCT04896320
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Tucatinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Clackamas, Oregon • Newberg, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional

Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study

NCT00256815
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
chemotherapy, Radiation
Drug · Procedure
Lead sponsor
Clinical Oncology Research Associates
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 25, 2026, 4:57 PM EDT
Terminated Phase 2 Interventional Results available

Trastuzumab and Vinorelbine in Advanced Breast Cancer

NCT01185509
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
trastuzumab, vinorelbine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 25, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

NCT00165334
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab, Vinorelbine (Navelbine)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Sep 25, 2026, 4:57 PM EDT